Novozymes' stock is declining for almost two years and has lost almost 50% of its previous value. The company reported mediocre half-year results for fiscal 2023. But Novozymes has a wide economic ...

Novozymes is increasing prices to counter soft demand and high costs, but end markets probably won't tolerate rising prices indefinitely. With generally weak input price inflation, Novozymes' stock ...